Cnp-38: Side Effects, Uses & Monitoring
YUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.
- Data source
- FDA labeling via NIH DailyMed (label e01c1197…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
YUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Frequently Asked Questions
What is Cnp-38 used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Cnp-38?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Cnp-38 require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Cnp-38.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.